MISONIX Inc. (MSON, Financial) filed Quarterly Report for the period ended 2012-12-31.
Misonix, Inc. has a market cap of $39.8324 million; its shares were traded at around $5.68 with a P/E ratio of 170.2 and P/S ratio of 2.3354. Misonix, Inc. had an annual average earning growth of 25.5% over the past 5 years.
Gross profit: Gross profit decreased to 56.9% for the six months ended December 31, 2012 from 59.6% for the six months ended December 31, 2011. The decrease is related to an unfavorable mix of high and low margin product deliveries in addition to the increase in minimum gross profit contribution requirement cost related to the Soma product, as a result of the settlement with Puricore International Limited (“PuriCore”) dated July 22, 2011.
Net sales: Net sales decreased $76,304 to $3,474,231 for the three months ended December 31, 2012 from $3,550,535 for the three months ended December 31, 2011. The decrease in sales is primarily related to lower Neuroaspirator revenue of $277,073, lower Autosonix revenue of $255,467 and lower Lysonix revenue of $198,118, partially offset by higher BoneScalpel revenue of $401,835, higher SonicOne™ revenue of $218,437 and higher Lithotripsy and service revenue of $32,841.
Set forth below are tables showing the Company’s net sales by (i) product category and (ii) geographic region for the three months ended December 31, 2012 and 2011:
Gross profit: Gross profit decreased to 53.2% for the three months ended December 31, 2012 from 63.9% for the three months ended December 31, 2011. The decrease in sales is related to unabsorbed factory costs due to lower sales volume, along with an unfavorable mix of low and high margin product deliveries in addition to the minimum gross profit margins requirement cost related to the Soma product as a result of the settlement with PuriCore dated July 22, 2011.
Read the The complete Report
Misonix, Inc. has a market cap of $39.8324 million; its shares were traded at around $5.68 with a P/E ratio of 170.2 and P/S ratio of 2.3354. Misonix, Inc. had an annual average earning growth of 25.5% over the past 5 years.
Highlight of Business Operations:
Net sales: Net sales increased $1,277,022 to $8,044,756 for the six months ended December 31, 2012 from $6,767,734 for the six months ended December 31, 2011. The increase in sales was primarily attributable to sales of the Company’s BoneScalpel™ products of $1,847,310, partially offset by lower Autosonix revenue of $624,713.Gross profit: Gross profit decreased to 56.9% for the six months ended December 31, 2012 from 59.6% for the six months ended December 31, 2011. The decrease is related to an unfavorable mix of high and low margin product deliveries in addition to the increase in minimum gross profit contribution requirement cost related to the Soma product, as a result of the settlement with Puricore International Limited (“PuriCore”) dated July 22, 2011.
Net sales: Net sales decreased $76,304 to $3,474,231 for the three months ended December 31, 2012 from $3,550,535 for the three months ended December 31, 2011. The decrease in sales is primarily related to lower Neuroaspirator revenue of $277,073, lower Autosonix revenue of $255,467 and lower Lysonix revenue of $198,118, partially offset by higher BoneScalpel revenue of $401,835, higher SonicOne™ revenue of $218,437 and higher Lithotripsy and service revenue of $32,841.
Set forth below are tables showing the Company’s net sales by (i) product category and (ii) geographic region for the three months ended December 31, 2012 and 2011:
Gross profit: Gross profit decreased to 53.2% for the three months ended December 31, 2012 from 63.9% for the three months ended December 31, 2011. The decrease in sales is related to unabsorbed factory costs due to lower sales volume, along with an unfavorable mix of low and high margin product deliveries in addition to the minimum gross profit margins requirement cost related to the Soma product as a result of the settlement with PuriCore dated July 22, 2011.
Read the The complete Report
